{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:14:05Z","timestamp":1778904845493,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102535","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:53:20Z","timestamp":1773590000000},"page":"102535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-4035","authenticated-orcid":false,"given":"Martin","family":"Zarba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Maj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3424-6585","authenticated-orcid":false,"given":"Razane El Hajj","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2315-8422","authenticated-orcid":false,"given":"Karl","family":"Semaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Connor","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-863X","authenticated-orcid":false,"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Pablo","family":"Sade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-6074","authenticated-orcid":false,"given":"Kosuke","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-8244","authenticated-orcid":false,"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-4571","authenticated-orcid":false,"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Basterretxea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2412-1563","authenticated-orcid":false,"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Y.C.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clgc.2026.102535_bib0001","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2026.102535_bib0002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clgc.2026.102535_bib0003","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102535_bib0004","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102535_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2025.09.006","article-title":"Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial","volume":"37","author":"Motzer","year":"2026","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102535_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101210","article-title":"Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma","volume":"8","author":"Haanen","year":"2023","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.clgc.2026.102535_bib0007","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus Pembrolizumab versus Sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102535_bib0008","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/JU.0000000000003132","article-title":"Characterization of patients with metastatic renal cell carcinoma experiencing complete response to first-line therapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"209","author":"Takemura","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102535_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00114","article-title":"Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials","volume":"3","author":"Pons-Tostivint","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102535_bib0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40425-017-0276-8","article-title":"Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials","volume":"5","author":"Kaufman","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"17","key":"10.1016\/j.clgc.2026.102535_bib0011","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2217\/imt-2021-0085","article-title":"Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report","volume":"13","author":"Pesola","year":"2021","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.clgc.2026.102535_bib0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102535_bib0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102535_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118875","article-title":"Immune checkpoint inhibition in renal cell carcinoma: mechanisms of resistance and emerging therapeutic strategies","volume":"193","author":"Darzi","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.clgc.2026.102535_bib0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2015.12.031","article-title":"Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis","volume":"70","author":"Buchler","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102535_bib0016","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/JCO.2022.40.16_suppl.4501","article-title":"Association between depth of response (DepOR) and clinical outcomes: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER","volume":"40","author":"Su\u00e1rez","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102535_bib0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2024.03.015","article-title":"Characterization of responses to Lenvatinib plus Pembrolizumab in patients with advanced renal cell carcinoma at the final prespecified survival analysis of the phase 3 CLEAR study","volume":"86","author":"Motzer","year":"2024","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102535_bib0018","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition","volume":"116","author":"Mancuso","year":"2006","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.clgc.2026.102535_bib0019","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"10.1016\/j.clgc.2026.102535_bib0020","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence \u2013 what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2026.102535_bib0021","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102535_bib0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2026.102535_bib0023","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/JU.0000000000003132","article-title":"Characterization of patients with metastatic renal cell carcinoma experiencing complete response to first-line therapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"209","author":"Takemura","year":"2023","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102535_bib0024","doi-asserted-by":"crossref","first-page":"pkaf069","DOI":"10.1093\/jncics\/pkaf069","article-title":"The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials","volume":"9","author":"Chang","year":"2025","journal-title":"JNCI Cancer Spectr"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:33:53Z","timestamp":1778902433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000352"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102535","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102535"}}